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Abstract
Background: The Aurora kinase family is comprised of highly con-
served serine/threonine protein kinases that are known to be crucial in 
the regulation of the cell cycle. Aberrant expression of Aurora kinases 
has been demonstrated in certain malignancies. We aimed to examine 
the expression of Aurora kinases in human breast cancer tissues and 
to investigate the cellular impact of Aurora kinases inhibitor on breast 
cancer cells.
Methods: The expression of Aurora kinase A/B/C was individually 
examined in tumor specimens (n = 106) and normal tissues (n = 29) 
from breast cancer patients using quantitative real-time PCR (Q-PCR) 
and immunohistochemistry. Cells were treated with the corresponding 
inhibitor, and then migration and adhesion were evaluated by electric 
cell impedance sensing assay. The proliferation of breast cancer cells 
treated with the inhibitor was examined using in vitro models.
Results: High levels of Aurora kinase B and C were found in the 
tumor tissues from breast cancer patients, but low levels of Aurora 
kinase A were seen in normal tissues at the mRNA level and immuno-
histochemistry. The mRNA expression level of Aurora kinase B and 
C had a negative correlation with grade staging, staging and survival 
rate in breast cancer patients, whilst Aurora kinase A exhibited a con-
verse expression. The inhibitor ZM447439 promoted adhesion of the 
human breast cancer cell line MDA-MB-231 and inhibited the migra-
tion of MCF-7 human breast cancer cells.
Conclusion: Taken together, the expression of Aurora kinase B and 
C was down-regulated in breast tumor tissues but Aurora kinase A 
was not. Aurora kinase may have a key role in the progression and 
metastasis of breast cancer.
Keywords: Breast cancer; Metastasis; Aurora kinases A, B and C; Im-
munohistochemistry; Migration; Adhesion; Proliferation; ZM447439
Introduction
As reported, breast cancer is the most common carcinoma and 
a life-threatening disorder in females with high rates of mor-
bidity and mortality due to distant metastasis. There are nu-
merous metastatic sites for breast cancer, such as brain, bone, 
liver and lung. Amongst these, bone metastasis is regarded as 
the most common complication in breast cancer [1-4]. How-
ever, the metastatic mechanism regulating this complex pro-
cess is little known. Therefore, understanding the mechanisms 
of metastatic disease is essential for the development of new 
diagnostic and therapeutic strategies.
The Aurora kinase family (Aurora A, B, and C) of highly 
conserved serine/threonine protein kinases are known to be 
crucial in the early stages of the mitotic cell cycle [5]. The Au-
rora kinase family consists of a regulatory N-terminal domain, 
a protein kinase domain and a C-terminal domain sharing high 
sequence homology and has a high degree of conserved func-
tional motifs [6-8]. The functional role of Aurora family is as-
sociated with their localization and specific substrate proteins 
binding to them [9].
Aberrant expression of Aurora kinases may interfere with 
mitosis and cytokinesis, and then lead to genetic instability; 
this in turn may result in the development of tumors. The Au-
rora kinase action mechanism is based on different isoform and 
cancer type [6]. It is reported that Aurora kinase A is overex-
pressed during breast cancer cell transformation [10, 11]. Also, 
high expression of Aurora A is also found in ovarian, colon and 
lung cancer [11, 12]. It is also found that aberrant expression of 
Aurora B is associated with thyroid anaplastic carcinoma [13], 
colon cancer [14] and oral cancer [15]. Aurora C plays a role 
in meiosis [16] and its overexpression is also associated with 
certain somatic cancers [17]. Aurora kinases are validated as a 
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therapeutic target for cancer and thus the development of Au-
rora kinase inhibitors has progressed from preclinical to clinical 
studies [17, 18]. After the discovery of the first Aurora kinase 
inhibitor ZM447494 as a potential drug in cancer treatment for 
targeted therapy, more than 30 Aurora kinase inhibitors have 
been identified in tumor treatment [19, 20]. Tavant et al indicat-
ed that Aurora kinases inhibitors VX-680 and ZM447439 were 
promising drug of potential clinical in connection with conven-
tional osteosarcoma chemotherapeutic agents via the analysis 
of these two inhibitors [21]. AT9283 is one kind of Aurora ki-
nases inhibitors, and it could inhibit Aurora kinases A and B, 
which has inhibition of proliferation and cellular division and 
the induction of apoptosis in cancer cells [22, 23]. ENMD-2076, 
another Aurora kinase inhibitor, has also been proved to inhibit 
cell growth and induce apoptosis in acute myeloid leukemia 
cells in vitro [24]. VX-680, also called MK0457, is a pan-Au-
rora kinase inhibitor that induces apoptosis and disrupts mito-
sis in cells cycling and plays an efficacious role in clinical like 
lymphomas and solid tumors. Recently, several studies showed 
VX-680 inhibition of tumor growth was associated with well-
tolerated doses, and no signs of mechanism-independent toxic-
ity were found [25-27]. Aurora kinases played key functions 
in the early phases of the mitotic cell cycle. Recent researches 
have demonstrated that the expression of Aurora kinases was 
valuable in targeted therapy development and disease stabiliza-
tion. There are numerous preclinical studies and multiple phase 
I and II clinical trials taking place in both hematologic and solid 
malignancies about Aurora kinase inhibitors.
In this study, we investigated the possible clinical impli-
cation of Aurora kinases in human breast tumor tissues and 
whether the expression level is related to the clinical outcome 
of patients with breast cancer. We also detected the effect of 
Aurora kinase on human breast tumor cells with Aurora kinase 
inhibitor ZM447439 in vitro.
Materials and Methods
Human breast specimens and ethics, consent and permis-
sions
Breast tissue samples were obtained immediately from breast 
cancer patients after surgery and snap frozen in liquid nitrogen 
for further use. The specimens included breast tumor tissues (n 
= 106) and normal background mammary tissues (n = 29) ob-
tained from the same patients. The pathology of these samples 
was confirmed by a pathologist and the background tissues were 
free from tumor deposits. All protocols were approved by the 
local ethics committee. Ethics were under the Bro Taf Health 
Authority (01/4303 and 01/4046). Full patient consent was ob-
tained. Full patient clinical data details are shown in Table 1.
Cell culture
Breast cancer cell lines BT549, MCF-7, MCF-10A and MDA-
MB-231 were purchased from the European Collection of Ani-
mal Cell Cultures (ECACC; Salisbury, UK). Invasions of MCF-7 
and BT-549 are low, while MDA-MB-231 represents high inva-
siveness, and MCF-10A is an immortalized mammary epithelial 
cell. Of these cell lines used, MCF-10A and MCF-7 are ER posi-
tive, while MDA-MB-231 and BT-549 are ER negative. MCF-
10A cells were cultured in mammary epithelial cell medium 
(Lonza Biologics Inc., Portsmouth, NH, USA), the remaining 
cells were routinely cultured in DMEM/F12 HAM with L-Glu-
tamine (Dulbecco’s modified Eagle’s medium; Sigma-Aldrich, 
Dorset, UK) supplemented with 10% fetal calf serum (FCS; PAA 
Laboratories, Somerset, UK), streptomycin (Sigma-Aldrich) and 
penicillin, in an incubator at 37 °C, 5% CO2 and 95% humidity.
Processing of tissues and extraction of RNA and generation 
of cDNA
Tissue specimens were homogenized in RNA extraction solu-
tion with hand held homogenizer to extract total RNA. RNA 
concentration was quantified using UV spectrophotometer. To-
tal cDNA was generated from 1 µg RNA using commercially 
available RT kit (AbGene Laboratories, Essex, England).
Immunohistochemical staining of Aurora kinase A, B and 
C in breast specimens
Frozen sections of breast tumor and background tissues were 
Table 1.  Breast Cancer Patient Clinical Data Details
Clinical data Sample no.
Tissue sample
  Normal 34
  Tumor 118
NPI
  1 63
  2 36
  3 15
Tumor grade
  1 21
  2 41
  3 7
TNM staging
  I 2
  II 36
  III 7
  IV 4
Survival status
  1 84
  2 6
  3 5
  4 16
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cut at a thickness of 6 µm using a cryostat (Leica Microsys-
tems (UK) Ltd, Bucks, UK). Briefly, immunohistochemistry 
staining followed the protocol as described previously [28].
The dilution chosen of primary antibodies and second-
ary antibody was based on evaluation test run, during which 
the antibodies were tested over a range from 1:10 to 1:1,000. 
Primary antibodies were omitted in negative controls. Follow-
ing cultured with antibodies, Avidin Biotin Complex (Vector 
Laboratories) was applied to the sections followed by exten-
sive washing. Diaminobenzidine chromogen (Vector Labs) 
was then added to the sections, which were kept in the dark 
for 5 min. Independent observers carried out the microvessels 
counts as we have reported in a study before [29].
Real-time reverse transcription quantitative PCR
Real-time quantitative PCR, based on the Amplifluor™ tech-
nology, was to quantify the mRNA expression level of Aurora 
kinases from above cDNA samples of breast tissues follow-
ing the method previous reported [30]. The pairs of Q-PCR 
primers were designed with Beacon Designer software which 
includes complementary sequence to universal Z probe (Inter-
gen Inc., Oxford, UK). The pair Q-PCR primers sequences are 
shown in Table 2. Real-time PCR was carried out using an 
IcyclerIQ™ (Bio-Rad, Hemel Hempstead, UK) kit with the 
following cycling conditions: 94 °C for 12 min, 60 cycles of 
94 °C for 15 s, 55 °C for 40 s (the data capture step) and 72 
°C for 20 s. The transcripts levels were generated from an in-
ternal standard which was simultaneously amplified with the 
samples.
Electric cell-substrate impedance sensing (ECIS) based 
analyses on cell adhesion and cell migration
The ECIS Ztheta system (Applied Biophysics Ltd, Troy, NJ, 
USA) evaluated cells adhesion and migration as described by 
Jiang et al before [31]. ECIS needed special 96-well W96E1 
microarrays. Following 100 µL DMEM medium with different 
concentration inhibitor (ZM447439: IC50 = 50 nM) added in 
a 96-well W96E1 microarray, BT-549, MCF-7, MCF-10A and 
MDA-MB-231 cells (40,000 per well) were separately seeded 
into wells of array. Live tracking of cell adhesion was carried 
out over a range of frequencies from 1,000 to 64,000 Hz using 
automated modules for 24 h. Confluent breast cancer cell mon-
olayers seeded in the arrays were electrically wounded (2,000 
mA for 20 s each). Following the track, migration of the cells 
was tracked over a range of frequencies for 5 h. All the experi-
ments were conducted at least three times.
In vitro cell growth assay
Cells suspension treated with different concentration inhibitor 
(ZM447439) was seeded into a 96-well plate (3,000 cells/200 
µL/well). Cell growth was assessed after a period of incuba-
tion in quadruplicate (overnight, day 3 and day 5). Four per-
cent formalin was used to fix cells and 0.5% crystal violet was 
used for stained cells. Crystal violet was extracted with 100 
µL 10% acetic acid and the absorbance of the dissolved dye 
determined using an ELx800 spectrophotometer (BIO-TEK, 
ELx800) at a wavelength of 540 nm.
Statistical analysis
Statistical analysis was carried out using the Minitab statistical 
software package (version 14) and Mann-Whitney test, whilst 
normally distributed data used t-test. Significant differences 
were taken at P<0.05.
Results
Expression of Aurora kinases in human breast cancer tis-
sues and the histopathological/clinical characteristics of 
the disease
The expression patterns of Aurora kinase A, B and C were ana-
lyzed in breast cancer tissues and adjacent normal tissues (tu-
mor, n = 118; background, n = 34) using real-time quantitative 
PCR (all values are displayed as mean Aurora kinase transcript 
copies/µL of cDNA from 50 ng total RNA). In comparison 
with normal background tissues, a significantly decreased ex-
pression of Aurora kinase A was found in breast tumor tissues 
(P = 0.05) (Fig. 1a). Aurora kinase A protein was observed in 
the cytoplasmic region of normal mammary epithelial cells, 
while stromal cells had very little staining. Immunochemical 
staining was conducted on a portion of paired normal back-
ground tissues and tumor tissues (n = 34 pairs). Intense ex-
pression of Aurora kinase A was primarily observed in normal 
background tissues compared with breast tumor tissues (Fig. 
1b). These results together suggested that Aurora kinase A is 
lowly expressed in breast cancer and may act a role in the pro-
gression of breast cancer.
We also analyzed the expression levels of Aurora B and 
Table 2.  Primers Sequences (Q-PCR)
Molecular Sense primers (5′-3′) Antisense primers (5′-3′)
Aurora kinase A GGTCAGTACATGCTCCATCT ACTGAACCTGACCGTACACAGAGATCCACCTTCTCATC
Aurora kinase B GCAGAGAGATCGAAATCCA ACTGAACCTGACCGTACAGGGGCATACTCTAGGAATCAA
Aurora kinase C TGGAGTGCTCTGCTATGAG ACTGAACCTGACCGTACCGTACAGCATTGATAGTGGAAACCTC
GAPDH (Q-PCR) CTGAGTACGTCGTGGAGTC ACTGAACCTGACCGTACAGAGATGATGACCCTTTTG
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C in paired normal tissues and breast tumor tissues within 
the same specimen. However, increased levels of Aurora B 
demonstrated a higher level in breast tissues than in normal 
background tissues (Fig. 2a), which were consistent with the 
immunohistochemistry results of Aurora B RNA transcript 
expression (Fig. 2b), and the difference was statistically sig-
nificant (P < 0.05). Also there was a significantly increased 
expression of Aurora kinase C in breast tumor tissues com-
pared with adjacent normal tissues (P = 0.05) (Fig. 2c). These 
results together suggested that Aurora kinase B and C are 
highly expressed in breast cancer. Taken together, the expres-
sion levels of Aurora kinase A, B and C are different in the 
same tissues though they belong to the same family. Thus, 
they may play different roles in the progression of breast can-
cer.
Correlation of Aurora kinase A expression with Notting-
ham prognostic index (NPI), grade, TNM staging and 
prognosis
To evaluate the relationship of Aurora kinase A expression 
with disease progression, we analyzed the level of Aurora ki-
nase A transcripts in connection with NPI, grade and TNM 
staging of breast tumors. NPI was used as an indicator to 
assess the relationship between Aurora kinase A transcript 
and a predicted prognosis. Based on the NPI value, breast 
cancer patients were divided into three groups: good (NPI-1), 
moderate (NPI-2) and poor prognosis (NPI-3). It was sug-
gested that the lowest level of Aurora kinase A was observed 
in patients with poor prognostic index (67.0 ± 28 copies/µL) 
among these three groups. The difference between patients 
with good prognosis and poor prognosis was highly signifi-
cant (P = 0.0092) (Fig. 3a). Although node negative tumors 
had higher levels of Aurora kinase A transcript (597.0 ± 391 
copies/µL) when compared with node positive tumors (111.0 
± 20 copies/µL), the difference was nonetheless insignificant 
(Fig. 3b).
We further evaluated the levels of Aurora kinase A tran-
script in connection with breast tumor grade. The expression 
level of Aurora kinase A was lowest in grade 3 (97.0 ± 15.7 
copies/µL) and grade 3 tumor had significantly lower levels 
compared with grade 1 (380.0 ± 177 copies/µL) breast tumors 
(P = 0.0401) (Fig. 3c). The relationship between Aurora kinase 
A and TNM status was also analyzed. Although the expression 
level of Aurora kinase A in TNM2, TNM3 and TNM4 was all 
lower than TNM1, statistical significant difference only disap-
peared in TNM2 tumor when compared with TNM1 tumor (P 
= 0.0292) (Fig. 3d).
Regarding the clinical outcomes at the final follow-up, 
the patients were divided into remaining disease free, with 
metastasis disease, with local recurrence and died of breast 
tumor after a median 120 months follow-up. Patients who 
developed tumor metastasis and local recurrence, and who 
died of breast cancer all had lower levels of Aurora kinase 
A. Patients with metastatic disease and with local recurrence 
showed significantly lower level in comparison with those 
who remained disease free (P = 0.021, P = 0.008) (Fig. 3e). 
Decreased transcript levels of Aurora kinase A was found in 
patients with poor prognosis and reached statistical signifi-
Figure 1. Expression of Aurora kinase A in breast cancer tissues. (a) Aurora kinase A transcripts level was decreased in human 
breast cancer. (b) Immunohistochemical staining of Aurora kinase A in normal breast tissue (left panel) and tumor tissue (right 
panel).
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cance (P = 0.05) (Fig. 3f).
Correlation of Aurora kinase B and C expression with NPI, 
grade staging and prognosis
We also analyzed the level of Aurora kinase B and C transcripts 
in connection with NPI, grade and TNM staging of breast tu-
mors. This showed that the highest level of Aurora kinase B 
transcript was seen in NPI-3 compared with NPI-1 and NPI-2 
(Fig. 4a). We also found that the expression level of Aurora 
kinase B was higher in grade 3 than in grade 1 and grade 2 
(Fig. 4b). Patients who died of breast cancer had the highest 
levels of Aurora kinase B (Fig. 4c). Increased transcript levels 
of Aurora kinase B were found in patients with poor prognosis 
(Fig. 4d). Although these tests did not reach statistical signifi-
cance, the increased tendency of Aurora kinase B expression 
level was clear in breast tumor tissues.
The expression level of Aurora kinase C was highest in 
poor prognostic index compared with good and moderate 
prognosis (Fig. 4e). There appeared to be a stepwise increase 
of levels of Aurora kinase C from grade 1 to grade 3 staging 
(Fig. 4f). Patients who developed local recurrence had higher 
Aurora kinase C expression level than those remaining disease 
free and with metastasis disease (Fig. 4g). Higher levels of Au-
rora kinase C were seen in patients with poor prognosis com-
pared with remaining disease free (Fig. 4h). The increased ten-
dency of Aurora kinase C expression level was clear in breast 
tumor tissues, though differences did not reach significant.
ECIS based cell adhesion and cell migration assay
To investigate the effects of Aurora kinases inhibitor 
ZM447439 on breast cell migration and adhesion, we adopted 
the ECIS method in tracking cell motility. As is shown in Fig-
ure 5a, MCF-7 cells treated with inhibitor ZM447439 showed 
a slowdown in recovery after electric wounding. 3D imaging 
confirmed the migration of MCF-7 cells. The migration abil-
ity of MCF-7 treated with ZM447439 (Fig. 5c, d) decreased 
compared with control group (no treatment) (Fig. 5b). We also 
analyzed other breast cancer cells such as MDA-MB-231, 
BT549 and MCF-10A, but the difference was not clear (data 
not shown).
There appeared some difference in adherence of MDA-
MB-231 cells when treated with Zm447439. The adherence 
of MDA-MB-231 cells treated with inhibitor ZM447439 in-
creased compared with the control group (no treatment) (Fig. 
Figure 2. Expression of Aurora kinase B and C in breast cancer tissues. (a) The expression of Aurora kinase B is higher in breast 
cancer tissues. (b) Immunohistochemical staining of Aurora kinase B in normal background tissue (left panel) and breast tumor 
tissue (right panel). (c) Aurora kinase C transcripts level was increased in human breast cancer.
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Figure 3. Correlation of Aurora kinase A expression with Nottingham prognostic index (NPI), grade, TNM staging and prognosis. 
(a) Lowest level of Aurora kinase A was observed in patients with poor prognostic index among these three groups (**P < 0.01 
NPI-3 vs. NPI-1). (b) Node negative tumors had higher levels of Aurora kinase A transcript than node positive tumor. (c) Levels 
of expression of Aurora kinase A in breast tumor tissues in connection with grade and (d) with TNM status (*P < 0.05 grade 3 vs. 
grade 1; *P < 0.05 TNM 2 vs. TNM 1). (e) Levels of Aurora kinase A transcript and clinical outcomes. Aurora kinase A expression 
progressively decreased in the patients with metastasis disease, with local recurrence and die of breast cancer, compared with 
patient with disease free (*P < 0.05 metastasis vs. disease free; **P < 0.01 local recurrence vs. disease free). (f) Lower level of 
Aurora kinase A expression in patients with poor prognosis.
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Figure 4. Correlation of Aurora kinase B and C expression with Nottingham prognostic index (NPI), grade staging and progno-
sis. Top panel (Aurora kinase B): (a) Highest level of Aurora kinase B in patients with poor prognostic index among these three 
groups. (b): Grade 3 tumor had higher level of Aurora kinase B transcript than grade 1 and 2. (c) Levels of Aurora kinase B tran-
script and clinical outcomes. Aurora kinase B expression progressively increased in the patients with local recurrence and die 
of breast cancer, compared with patient with disease free. (d) Higher level of Aurora kinase B expression in patients with poor 
prognosis. Bottom panel (Aurora kinase C): (e) Higher level of Aurora kinase C in patients with poor prognostic index than with 
moderate and poor prognosis. (f) A stepwise increase of levels of Aurora kinase C was found from grade 1 to grade 3 staging. (g) 
Lever of Aurora kinase C expression was higher in the patients with local recurrence than with metastasis disease and disease 
free. (h) Lower level of Aurora kinase C expression in patients with good prognosis.
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Figure 5. Effects of Aurora kinases inhibitor on the adhesion of breast cancer cells. Top panel: The response of MCF-7 to 
ZM447439. (a) Migration traces of MCF-7 cell’s response to ZM447439 at different concentrations. (b) 3D image of MCF-7 (con-
trol); (c and d) Response of MCF-7 to ZM447439 at 50 and 500 nM, respectively. Bottom panel: The response of MDA-MB-231 
to ZM447439. (e) Traces of MDA-MB-231 cell’s response to ZM447439 at different concentrations. (f) 3D image of MDA-MB-231 
(control); (g and h) Response of MDA-MB-231 to ZM447439 at 50 and 500 nM, respectively.
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5e). In 3D imaging, it was confirmed (Fig. 5f, g, h). In com-
parison with control group (no treatment), higher level of ad-
hesion was found in MDA-MB-231 cell group treated with in-
hibitor ZM447439. We also analyzed the effect of ZM447439 
on proliferation and invasion of breast cancer cells, but this did 
not reach statistical significance (data not shown).
Discussion
In this study, we have demonstrated that Aurora kinase A had 
lower expression levels in human breast tumor tissues com-
pared with normal background tissues. Aurora kinase B and C 
were also aberrantly expressed in clinical breast tumor tissues; 
however, both of them showed higher expression in breast 
tumor tissues than in adjacent normal tissues. The abnormal 
expression of Aurora kinases in breast tumor tissues may act a 
role in the progression of breast cancer.
The relationship between the level of Aurora kinase ex-
pression and clinical outcome is an important observation. An 
inverse correlation was found between the level of the Aurora 
kinase A transcript and tumor grade and TNM staging. Howev-
er, the relationship between Aurora kinase B and C expression 
level had a positive correlation. The levels of Aurora kinase 
B and C were correlated with the clinical outcomes and long 
term survival of breast cancer patients, but Aurora kinase A 
was opposite. According to analysis of the clinical data, Au-
rora kinases may act as a potential prognostic indicator in pa-
tients with breast tumor.
Recently, some reports have shown that the role of Aurora 
kinases is to act in some cancer and signaling pathways. A new 
study showed KRAS could induce knockdown of Aurora ki-
nase A and B in the KRAS-positive lung cancer cell lines H358 
and A549. Furthermore, the growth, proliferation, transforma-
tion and viability levels of these two cell lines decreased when 
treated with Aurora kinase A and B inhibitors in vitro. This 
suggested that Aurora kinases were important KRAS targets 
in lung cancer and Aurora kinases inhibition therapy may spe-
cially target KRAS-transformed cells [32]. However, another 
study found overexpression in 73% of the examined specimens. 
Furthermore, the expression of Aurora kinase A decreased tax-
ane sensitivity [33]. Aurora kinase A has also been shown to 
play a novel non-mitotic role in promoting tumor progression 
via activation of epithelial-mesenchymal transition reprogram-
ing. This resulted in the genesis of tumor-initiating cells [34]. 
In our research, however, the expression level of Aurora kinase 
A decreased in breast cancer tissues samples. Thus, the role 
of Aurora kinase A playing in breast cancer is unclear. In our 
current study, we detected the effect of Aurora kinase inhibitor 
ZN447439 on the motility of breast cancer cells. We found that 
the adherence of MDA-MB-231 cells decreased when treated 
with ZM447439. ZM447439 promoted the migration of MCF-
7 cells. We also analyzed the effect of ZM447439 on prolifera-
tion and invasion of breast cancer cells, but the difference was 
not significant. Interestingly, the results in vitro are associated 
with clinical outcome of human breast cancer.
In conclusion, Aurora kinases act as regulators of cellular 
motility of breast cancer cells. With cells treated with inhibitor 
ZM447439, we predicted that Aurora kinases inhibitor could 
inhibit tumor metastasis by reducing migration of breast can-
cer cells. Together with the clinical relevance as demonstrated 
above, Aurora kinases play an important role as prognostic 
indicators and may be an important target when considering 
therapies.
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